One is to promote tumor antigen recognition and presentation, such as using GM-CSF, toll-like receptor agonists; The other is to eliminate the immunosuppressive factors in the tumor microenvironment, mainly by using immune checkpoint inhibitors, such as CTLA-4 inhibitors and PD-1/PD-L1 inhibitors. This evidence concerns the gene CTLA4 and neoplasm.